Recent data suggest that the inhibition of the PI3KAkt pathway by everolimus results in increased activity of Foxo proteins that up-regulate Foxp3 expression (reviewed in ref.30). == Specific Growth of Treg in Vivo. be considered regulatory T cells as well. The combined use of everolimus and IL-2/IL-2ab complexes in vivo makes it feasible to achieve highly effective antigen-driven conversion of naive T cells into Treg and their growth in vivo and thereby the explained protocols constitute important tools to achieve immunological tolerance by Treg vaccination. Keywords:antigen-specific Treg conversion, Foxp3, IL-2/IL-2ab complexes, mammalian target of rapamycin, prospective tolerance At present it is unclear how much the conversion of naive T cells into Treg in peripheral lymphoid tissue contributes to the control of immunity by Treg. On the other hand, it seems affordable to exploit Rabbit polyclonal to DPYSL3 this conversion process to control unwanted immune responses. In the past our lab Ro 10-5824 dihydrochloride has described several strategies to induce such conversion by exogenous antigens with the aim to study whether Treg conversion can be used to induce tolerance to antigens, including transplantation antigens, prospectively (13). We were successful in using this approach to induce prospective tolerance in female mice to a Ro 10-5824 dihydrochloride variety of male tissues, including skin and hematopoetic grafts (4). With regard to mechanisms it became Ro 10-5824 dihydrochloride obvious that Treg conversion in vivo is best achieved by subimmunogenic delivery of strong agonists under conditions that avoid functional activation of antigen presenting cells (59). Also, in accordance with more recent data (10), in this setting, best conversion is seen in T cells that undergo only limited proliferation, whereas higher doses of the strong agonist result in more considerable proliferation and diminished conversion (5). Thus these studies that addressed Treg conversion by monitoring the generation of Foxp3-expressing Treg in vivo confirmed anecdotal evidence of generating dominant tolerance by subimmunogenic antigen delivery (10). Comparison of such converted Treg with Treg generated by T-cell activation in vitro in the presence of relatively high doses of transforming growth factor beta TGF (12) showed that in vitro-generated Treg exhibited noticeable differences: the in vitro conversion process was much faster and resulted in Treg with unstable Foxp3 expression that correlated with lack of demethylation of the Foxp3 locus, whereas the in vivo method resulted in total demethylation and stable Foxp3 expression (13). In fact in some aspects the in vivo protocol was more akin to a different in vitro conversion method where T-cell activation was limited for an initial 18-h culture period in the absence of exogenously added TGF and activation of the PI3 kinase pathway was limited (14). Because stability of Foxp3 expression appeared mandatory for the induction of prospective tolerance, we thought to make the in vivo conversion more efficient with drugs that would either enhance the conversion process or expand already converted cells because previous analyses had shown that converted cells could be easily expanded in vivo even under conditions when antigens were delivered in an immunogenic context (2,3,5). The results show that in vivo Treg conversion can be markedly enhanced by drugs that interfere with signals generated through the phosphatidyl inositol 3 kinase (PI3K) pathway and that converted Treg can be expanded by drugs that induce strong proliferation. With regard to growth of Treg by IL-2/IL-2 ab complexes, we focused our attention around the properties of CD25+Foxp3cells that could symbolize activated, cytokine-producing effector cells. The results, however, show that these cells resemble regulatory T cells in that they are anergic and secrete either no or only suppressive cytokines. == Results and Conversation == == Enhancing Treg Conversion in Vivo. == Because costimulation is usually counterproductive to Treg conversion in vivo (5) and because in vitro results showed that interference with the PI3K pathway, especially inhibition of the mammalian target of rapamycin (mTOR), could impact Treg conversion (1416), we delivered antigen either by osmotic minipumps or DEC205 fusion antibodies in combination with or without the rapamycin analog everolimus, which inhibits mTOR. Everolimus was given for 14 d either together with the peptide when peptide was delivered by osmotic minipumps or after antigen was delivered at day 1 in the form of 40 ng of DEC205 fusion antibody. As a readout, two T-cell receptor (TCR) transgenic systems coupled with a Foxp3 reporter (17) were used; i.e., either female Marilyn mice (18) that express TCR transgenes encoding a receptor specific for HY peptide offered by I-AbMHC complexes and also expressed a Foxp3 reporter knockin. Alternatively, we used naive T cells expressing an HA-specific TCR (19) and the Foxp3 reporter, which were transferred into congenic unmanipulated BALB/c mice before injection with 40 ng of DEC205 antibody fused with the HA peptide. As.